{"id":25235,"date":"2014-06-10T07:26:33","date_gmt":"2014-06-10T11:26:33","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=25235"},"modified":"2014-06-10T07:26:33","modified_gmt":"2014-06-10T11:26:33","slug":"the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235","title":{"rendered":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/10\/2014 (wallstreetpr) \u2013<b> Pharmacyclics, Inc. (NASDAQ:PCYC)<\/b> announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application in support of the review of its drug IMBRUVICA for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma for complete approval. The supplemental NDA is useful in the therapy of patients who have received at least one treatment previously.<\/p>\n<p style=\"text-align: justify;\"><b>FDA\u2019s Approval<\/b><\/p>\n<p style=\"text-align: justify;\">Pharmacyclics, Inc. (NASDAQ:PCYC) had submitted the supplemental NDA to the FDA on the basis of data it had obtained from\u00a0the multi-center, randomized, open label last phase RESONATE\u2122 trial, PCYC-1112-CA, which was a strict comparison of IMBRUVICA\u2122 and ofatumumab. The study involved 391 patients diagnosed with CLL or SLL and all of whom had received at least one therapy previously. The FDA seeks to finalize reviewing the application as per the target date laid down by the Prescription Drug User Fee Act which is Oct 7, 2014.<\/p>\n<p style=\"text-align: justify;\">IMBRUVICA, which is the first drug to be filed for approval by the FDA via the novel Breakthrough Therapy Designation conduit, was approved for prior treated MCL in Nov, 2013. It was also approved by the FDA for prior treated CLL, which is the commonest form of leukemia found in adults in the Western countries, in February this year. The pathway through which the drug was filed with the FDa for approval ensures Pharmacyclics, Inc. (NASDAQ:PCYC) the quickest delivery of the medicine to the patients.<\/p>\n<p style=\"text-align: justify;\"><b>Compelling Data<\/b><\/p>\n<p style=\"text-align: justify;\">The company\u2019s Global Regulatory Affairs\u2019 Senior Vice President, Dr. Urte Gayko,\u00a0said that the company is expecting to continue work with the FDA after they finish the review procedure. He believes that the data the company has submitted is compelling to provide it the desired outcome of the review.<\/p>\n<p style=\"text-align: justify;\">Soon after Pharmacyclics, Inc. (NASDAQ:PCYC) announced the news today, of the FDA approving the company\u2019s supplemental NDA filing, its shares increased 3.8% and surged up to as much as 97.07.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/10\/2014 (wallstreetpr) \u2013 Pharmacyclics, Inc. (NASDAQ:PCYC) announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":25236,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1743,7045,5774],"stock_ticker":[],"class_list":["post-25235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqpcyc","tag-pharmacyclics-inc","tag-pharmacyclics-inc-nasdaqpcyc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/10\/2014 (wallstreetpr) \u2013 Pharmacyclics, Inc. (NASDAQ:PCYC) announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-10T11:26:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"378\" \/>\n\t<meta property=\"og:image:height\" content=\"133\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA\",\"datePublished\":\"2014-06-10T11:26:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg\",\"keywords\":[\"NASDAQ:PCYC\",\"Pharmacyclics Inc.\",\"Pharmacyclics Inc. (NASDAQ:PCYC)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\",\"name\":\"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg\",\"datePublished\":\"2014-06-10T11:26:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg\",\"width\":378,\"height\":133},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235","og_locale":"en_US","og_type":"article","og_title":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA  - Wall Street PR","og_description":"Boston, MA 06\/10\/2014 (wallstreetpr) \u2013 Pharmacyclics, Inc. (NASDAQ:PCYC) announced that the U.S. Food and Drug Administration has agreed to file its supplemental New Drug Application [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-10T11:26:33+00:00","og_image":[{"width":378,"height":133,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA","datePublished":"2014-06-10T11:26:33+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg","keywords":["NASDAQ:PCYC","Pharmacyclics Inc.","Pharmacyclics Inc. (NASDAQ:PCYC)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235","url":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235","name":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg","datePublished":"2014-06-10T11:26:33+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/phra.jpg","width":378,"height":133},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/the-fda-approves-pharmacyclics-inc-nasdaqpcycs-filing-for-supplemental-new-drug-application-for-drug-imbruvica-25235#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"The FDA Approves Pharmacyclics, Inc. (NASDAQ:PCYC)\u2019s Filing For Supplemental New Drug Application For Drug IMBRUVICA"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=25235"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25235\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/25236"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=25235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=25235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=25235"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=25235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}